메뉴 건너뛰기




Volumn 94, Issue 3, 2004, Pages 14-15

Hormonal treatment alone for locally advanced prostate cancer

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; PROSTATE SPECIFIC ANTIGEN;

EID: 11144221991     PISSN: 14655101     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper
Times cited : (3)

References (15)
  • 2
    • 0035915453 scopus 로고    scopus 로고
    • Factors associated with initial therapy for clinically localized prostate cancer
    • Harlan LC, Potosky A, Gilliland FD et al. Factors associated with initial therapy for clinically localized prostate cancer. J Natl Cancer Inst 2001; 93: 1864-71
    • (2001) J Natl Cancer Inst , vol.93 , pp. 1864-1871
    • Harlan, L.C.1    Potosky, A.2    Gilliland, F.D.3
  • 3
    • 0023726635 scopus 로고
    • Hormone therapy for prostate cancer: Results of the Veterans Administration Cooperative Urological Research Group studies
    • Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr 1988; 7: 165-70
    • (1988) NCI Monogr , vol.7 , pp. 165-170
    • Byar, D.P.1    Corle, D.K.2
  • 4
    • 0031403675 scopus 로고    scopus 로고
    • Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council Trial
    • The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol 1997; 79: 235-46
    • (1997) Br J Urol , vol.79 , pp. 235-246
  • 5
    • 1042284728 scopus 로고    scopus 로고
    • Early versus delayed endocrine treatment in pN1-3M0 prostate cancer without local treatment of the primary tumor. Results of EORTC 30846 - A phase III study
    • Abstract 1487
    • Schröder FH, Kurth KH, Fossa SD et al. Early versus delayed endocrine treatment in pN1-3M0 prostate cancer without local treatment of the primary tumor. Results of EORTC 30846 - a phase III study. J Urol 2003; 169: 398 (Abstract 1487)
    • (2003) J Urol , vol.169 , pp. 398
    • Schröder, F.H.1    Kurth, K.H.2    Fossa, S.D.3
  • 6
    • 0033540004 scopus 로고    scopus 로고
    • Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer
    • Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999; 341: 1781-8
    • (1999) N Engl J Med , vol.341 , pp. 1781-1788
    • Messing, E.M.1    Manola, J.2    Sarosdy, M.3    Wilding, G.4    Crawford, E.D.5    Trump, D.6
  • 7
    • 0036845696 scopus 로고    scopus 로고
    • Timing of androgen deprivation for prostate cancer: Benefits versus side effects - A patient-physician dialogue
    • Soloway MS. Timing of androgen deprivation for prostate cancer: benefits versus side effects - a patient-physician dialogue. Urology 2002; 60: 735-7
    • (2002) Urology , vol.60 , pp. 735-737
    • Soloway, M.S.1
  • 8
    • 1042307986 scopus 로고    scopus 로고
    • Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: Results of a randomized prospective multicenter clinical trial
    • Waltregny D, Boca P, Nicolas H et al. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a randomized prospective multicenter clinical trial. J Urol 2002; 167: 175
    • (2002) J Urol , vol.167 , pp. 175
    • Waltregny, D.1    Boca, P.2    Nicolas, H.3
  • 9
    • 0034005784 scopus 로고    scopus 로고
    • Intermittent androgen deprivation in prostate cancer patients: Factors predictive of prolonged time off therapy
    • Strum SB, Scholz MC, McDermed JE. Intermittent androgen deprivation in prostate cancer patients: factors predictive of prolonged time off therapy. Oncologist 2000; 5: 45-52
    • (2000) Oncologist , vol.5 , pp. 45-52
    • Strum, S.B.1    Scholz, M.C.2    McDermed, J.E.3
  • 10
    • 0033816325 scopus 로고    scopus 로고
    • Prolonged response to a single androgen suppression phase in a subpopulation of prostate cancer patients
    • Theyer G, Ulsperger E, Baumgartner G, Raderer M, Hamilton G. Prolonged response to a single androgen suppression phase in a subpopulation of prostate cancer patients. Ann Oncol 2000; 11: 877-81
    • (2000) Ann Oncol , vol.11 , pp. 877-881
    • Theyer, G.1    Ulsperger, E.2    Baumgartner, G.3    Raderer, M.4    Hamilton, G.5
  • 11
    • 0142228727 scopus 로고    scopus 로고
    • Intermittent maximal androgen blockade in patients with metastatic prostate cancer: An EORTC feasibility study
    • Albrecht W, Collette L, Fava C et al. Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility study. Eur Urol 2003; 44: 505-11
    • (2003) Eur Urol , vol.44 , pp. 505-511
    • Albrecht, W.1    Collette, L.2    Fava, C.3
  • 12
    • 0033662035 scopus 로고    scopus 로고
    • Intermittent androgen suppression in the treatment of metastatic prostate cancer
    • Bouchot O, Lenormand L, Karam G et al. Intermittent androgen suppression in the treatment of metastatic prostate cancer. Eur Urol 2000; 38: 543-9
    • (2000) Eur Urol , vol.38 , pp. 543-549
    • Bouchot, O.1    Lenormand, L.2    Karam, G.3
  • 13
    • 0030071467 scopus 로고    scopus 로고
    • A prospective, randomised study to compare goserelin acetate (Zoladex) versus cyproterone acetate (Cyprostat) versus a combination of the two in the treatment of metastatic prostatic carcinoma
    • Thorpe SC, Azmatullah S, Fellows GJ, Gingell JC, O'Boyle PJ. A prospective, randomised study to compare goserelin acetate (Zoladex) versus cyproterone acetate (Cyprostat) versus a combination of the two in the treatment of metastatic prostatic carcinoma. Eur Urol 1996; 29: 47-54
    • (1996) Eur Urol , vol.29 , pp. 47-54
    • Thorpe, S.C.1    Azmatullah, S.2    Fellows, G.J.3    Gingell, J.C.4    O'Boyle, P.J.5
  • 14
    • 0033782359 scopus 로고    scopus 로고
    • Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 Years of follow-up
    • Iversen P, Tyrrell CJ, Kaisary AV et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of follow-up. J Urol 2000; 164: 1579-82
    • (2000) J Urol , vol.164 , pp. 1579-1582
    • Iversen, P.1    Tyrrell, C.J.2    Kaisary, A.V.3
  • 15
    • 0036855879 scopus 로고    scopus 로고
    • Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: Updated results of a multicentric trial
    • Boccardo F, Barichello M, Battaglia M et al. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial. Eur Urol 2002; 42: 481-90
    • (2002) Eur Urol , vol.42 , pp. 481-490
    • Boccardo, F.1    Barichello, M.2    Battaglia, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.